{"id":30403,"date":"2019-06-12T17:31:00","date_gmt":"2019-06-12T17:31:00","guid":{"rendered":"https:\/\/beyondtype2.org\/resources\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/"},"modified":"2019-06-12T17:31:00","modified_gmt":"2019-06-12T17:31:00","slug":"pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer","status":"publish","type":"resources","link":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/","title":{"rendered":"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p><b>Nombre del Estudio:<\/b><span style=\"font-weight: 400\"> Semalglutida Oral &ndash; Ensayo en Programa PIONEER&nbsp;<\/span><\/p>\n<div class=\"jhH5U r-i8NR8qaUG34k\" data-rtid=\"i8NR8qaUG34k\">\n<div id=\"tw-ob\" class=\"tw-src-ltr\">\n<div class=\"oSioSc\">\n<div id=\"tw-target\">\n<div id=\"kAz1tf\" class=\"g9WsWb\">\n<div id=\"tw-target-text-container\" class=\"tw-ta-container tw-nfl\">\n<p id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\"><strong>Objetivo del Estudio<\/strong>: Probar la efectividad del primer GLP-1 administrado por v&iacute;a oral, semaglutida oral, contra el placebo en la salud cardiovascular, particularmente los eventos cardiovasculares adversos mayores (MACE), como la primera aparici&oacute;n de muerte cardiovascular, ataques card&iacute;acos no fatales y no mortales carrera.<\/span><\/p>\n<div class=\"jhH5U r-i8NR8qaUG34k\" data-rtid=\"i8NR8qaUG34k\">\n<div id=\"tw-ob\" class=\"tw-src-ltr\">\n<div class=\"oSioSc\">\n<div id=\"tw-target\">\n<div id=\"kAz1tf\" class=\"g9WsWb\">\n<div id=\"tw-target-text-container\" class=\"tw-ta-container tw-nfl\">\n<p id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\"><strong>Antecedentes del estudio:<\/strong> El uso de agonistas de GLP-1 como un m&eacute;todo de tratamiento ha demostrado ser efectivo en el tratamiento de la diabetes tipo 2. En ensayos cl&iacute;nicos realizados durante los &uacute;ltimos 3 a 5 a&ntilde;os, este medicamento ha sido eficaz en la prevenci&oacute;n de eventos cardiovasculares, incluida la muerte. Los medicamentos de GLP-1 son Victoza (Liraglutida), Byetta (Exenatida), y Trulicity (Dulaglutida). <a href=\"https:\/\/www.mdedge.com\/endocrinology\/article\/193240\/diabetes\/oral-glp-1-receptor-agonist-pioneered-t2dm-trial\" target=\"_blank\" rel=\"noopener noreferrer\">Estudios previos mostraron que la semaglutida oral tambi&eacute;n tiene efectos reductores de la A1c.<\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"jhH5U r-i8NR8qaUG34k\" data-rtid=\"i8NR8qaUG34k\">\n<div id=\"tw-ob\" class=\"tw-src-ltr\">\n<div class=\"oSioSc\">\n<div id=\"tw-target\">\n<div id=\"kAz1tf\" class=\"g9WsWb\">\n<div id=\"tw-target-text-container\" class=\"tw-ta-container tw-nfl\">\n<p id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\"><strong>M&eacute;todos de estudio:<\/strong> m&aacute;s de 3,100 personas con diabetes Tipo 2 con elevado riesgo de eventos cardiovasculares aleatorizadas para recibir placebo o el medicamento mismo que est&aacute; a&uacute;n en espera de aprobaci&oacute;n de la FDA.&nbsp;<\/span><\/p>\n<div class=\"jhH5U r-i8NR8qaUG34k\" data-rtid=\"i8NR8qaUG34k\">\n<div id=\"tw-ob\" class=\"tw-src-ltr\">\n<div class=\"oSioSc\">\n<div id=\"tw-target\">\n<div id=\"kAz1tf\" class=\"g9WsWb\">\n<p><strong>Resultados:<\/strong><\/p>\n<ul>\n<li id=\"tw-target-text\" class=\"tw-data-text tw-ta tw-text-small\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\">Los resultados mostraron que la semaglutida oral no aumenta el riesgo de eventos cardiovasculares adversos importantes. En comparaci&oacute;n con un placebo, el riesgo de los resultados primarios a continuaci&oacute;n muestra: <\/span><\/li>\n<li class=\"tw-data-text tw-ta tw-text-small\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\">Muerte cardiovascular: 15 eventos con semaglutida oral (0,9%) frente a 30 eventos (1,9%) con placebo. <\/span><\/li>\n<li class=\"tw-data-text tw-ta tw-text-small\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\">Accidentes cerebrovasculares no mortales: 12 eventos con semaglutida oral (0,8 %) frente a 16 eventos (1,0%) con placebo. Ataques card&iacute;acos no fatales: 37 eventos con semaglutida oral (2,3%) frente a 31 eventos (1,9%) con placebo.<\/span><\/li>\n<\/ul>\n<p class=\"tw-data-text tw-ta tw-text-small\" dir=\"ltr\" data-placeholder=\"Traducci&oacute;n\"><span lang=\"es\"> Esto se determin&oacute; como no significativamente diferente al placebo.<\/span><\/p>\n<div id=\"tw-target-text-container\" class=\"tw-ta-container tw-nfl\">\n<pre class=\"tw-ta tw-text-small\"><\/pre>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>ADA_News<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Nombre del Estudio: Semalglutida Oral &ndash; Ensayo en Programa PIONEER&nbsp; Objetivo del Estudio: Probar la efectividad del primer GLP-1 administrado por v&iacute;a oral, semaglutida oral, contra el placebo en la salud cardiovascular, particularmente los eventos cardiovasculares adversos mayores (MACE), como la primera aparici&oacute;n de muerte cardiovascular, ataques card&iacute;acos no fatales y no mortales carrera. [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":30404,"comment_status":"open","ping_status":"open","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-30403","resources","type-resources","status-publish","has-post-thumbnail","hentry","diabetes-types-tipo-2","tags-ada_news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER | Beyond Type 1<\/title>\n<meta name=\"description\" content=\"Los resultados del primer receptor de GLP-1 muestran que es posible que aumenten el riesgo de eventos cardiovasculares en personas con diabetes tipo 2.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER | Beyond Type 1\" \/>\n<meta property=\"og:description\" content=\"Los resultados del primer receptor de GLP-1 muestran que es posible que aumenten el riesgo de eventos cardiovasculares en personas con diabetes tipo 2.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/\" \/>\n<meta property=\"og:site_name\" content=\"Beyond Type 1\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/beyondtype1\" \/>\n<meta property=\"og:image\" content=\"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-ESPANOL-HEADER-ADA-2019-12.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2048\" \/>\n\t<meta property=\"og:image:height\" content=\"733\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@BeyondType1\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/\",\"name\":\"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER | Beyond Type 1\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BT1-ESPANOL-HEADER-ADA-2019-12.png\",\"datePublished\":\"2019-06-12T17:31:00+00:00\",\"description\":\"Los resultados del primer receptor de GLP-1 muestran que es posible que aumenten el riesgo de eventos cardiovasculares en personas con diabetes tipo 2.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BT1-ESPANOL-HEADER-ADA-2019-12.png\",\"contentUrl\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BT1-ESPANOL-HEADER-ADA-2019-12.png\",\"width\":2048,\"height\":733},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/\",\"name\":\"Beyond Type 1\",\"description\":\"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.\",\"publisher\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#organization\",\"name\":\"Beyond Type 1\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/header-logo.svg\",\"contentUrl\":\"https:\\\/\\\/beyondtype1.org\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/header-logo.svg\",\"width\":56,\"height\":56,\"caption\":\"Beyond Type 1\"},\"image\":{\"@id\":\"https:\\\/\\\/beyondtype1.org\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/beyondtype1\",\"https:\\\/\\\/x.com\\\/BeyondType1\",\"http:\\\/\\\/instagram.com\\\/BeyondType1\\\/\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/BeyondType1\",\"https:\\\/\\\/www.tiktok.com\\\/@beyondtype1\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/beyond-type1\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER | Beyond Type 1","description":"Los resultados del primer receptor de GLP-1 muestran que es posible que aumenten el riesgo de eventos cardiovasculares en personas con diabetes tipo 2.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/","og_locale":"es_ES","og_type":"article","og_title":"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER | Beyond Type 1","og_description":"Los resultados del primer receptor de GLP-1 muestran que es posible que aumenten el riesgo de eventos cardiovasculares en personas con diabetes tipo 2.","og_url":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/","og_site_name":"Beyond Type 1","article_publisher":"https:\/\/www.facebook.com\/beyondtype1","og_image":[{"width":2048,"height":733,"url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-ESPANOL-HEADER-ADA-2019-12.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@BeyondType1","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/","url":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/","name":"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER | Beyond Type 1","isPartOf":{"@id":"https:\/\/beyondtype1.org\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/#primaryimage"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/#primaryimage"},"thumbnailUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-ESPANOL-HEADER-ADA-2019-12.png","datePublished":"2019-06-12T17:31:00+00:00","description":"Los resultados del primer receptor de GLP-1 muestran que es posible que aumenten el riesgo de eventos cardiovasculares en personas con diabetes tipo 2.","breadcrumb":{"@id":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/#primaryimage","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-ESPANOL-HEADER-ADA-2019-12.png","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2024\/11\/BT1-ESPANOL-HEADER-ADA-2019-12.png","width":2048,"height":733},{"@type":"BreadcrumbList","@id":"https:\/\/beyondtype1.org\/es\/pruebas-de-primer-receptor-oral-glp-1-para-dt2-resultados-del-programa-pioneer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beyondtype1.org\/es\/"},{"@type":"ListItem","position":2,"name":"Pruebas de Primer Receptor Oral GLP-1 para DT2- Resultados del Programa PIONEER"}]},{"@type":"WebSite","@id":"https:\/\/beyondtype1.org\/es\/#website","url":"https:\/\/beyondtype1.org\/es\/","name":"Beyond Type 1","description":"Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research.","publisher":{"@id":"https:\/\/beyondtype1.org\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beyondtype1.org\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/beyondtype1.org\/es\/#organization","name":"Beyond Type 1","url":"https:\/\/beyondtype1.org\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/","url":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","contentUrl":"https:\/\/beyondtype1.org\/wp-content\/uploads\/2025\/08\/header-logo.svg","width":56,"height":56,"caption":"Beyond Type 1"},"image":{"@id":"https:\/\/beyondtype1.org\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/beyondtype1","https:\/\/x.com\/BeyondType1","http:\/\/instagram.com\/BeyondType1\/","https:\/\/www.youtube.com\/c\/BeyondType1","https:\/\/www.tiktok.com\/@beyondtype1","https:\/\/www.linkedin.com\/company\/beyond-type1\/"]}]}},"_links":{"self":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/30403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/types\/resources"}],"author":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/comments?post=30403"}],"version-history":[{"count":0,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/resources\/30403\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media\/30404"}],"wp:attachment":[{"href":"https:\/\/beyondtype1.org\/es\/wp-json\/wp\/v2\/media?parent=30403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}